|
ASA Supports USG on WTO Ruling against the EU on
Biotechnology
January 24, 2008… Saint Louis, Missouri… The American Soybean
Association (ASA) supports the recent decision by the United States
government to give the European Union (EU) more time to implement a
science-based approval system for biotech-derived agricultural products,
but warns of dire consequences for European livestock industries if the
EU doesn’t speed up its approval process.
"ASA supports the decision of U.S. trade officials to temporarily
suspend action to withdraw concessions for the failures of the European
Union to bring its biotech approval process into compliance with the WTO
panel ruling," said ASA First Vice President Johnny Dodson, a soybean
producer from Halls, Tenn., who is the Chair of ASA’s Biotechnology
Working Group.
In May 2003, the United States filed a World Trade Organization (WTO)
case against the EU’s failure to implement a timely, science-based
approval system for food and feed products enhanced through
biotechnology. Numerous other countries, including Argentina, Australia,
Canada, Chile, Colombia, El Salvador, Honduras, Mexico, New Zealand,
Peru and Uruguay joined the United States in the complaint because they
also want to ensure that science-based determinations are applied to
regulatory decisions. On September 29, 2006, the WTO ruled the EU had
failed to meet its WTO obligations of implementing a timely,
science-based system for the approval of biotech-enhanced agricultural
products. The decision finalized a preliminary WTO ruling made in
February 2006.
"ASA has been in close contact with the U.S. Trade Representative
urging this course of action," Dodson said. "This is only a temporary
suspension to allow the EU to demonstrate through action that it
is making its system timely, and that decisions are being made on the
basis of science, not politics."
The continuing failure of the EU to bring its biotech approval system
into compliance not only will result in massive retaliation on EU
exports to the U.S. market, but also will result in devastating
consequences for the EU livestock and feed industries that are dependent
on imported oilseeds and feedstuffs.
The EU’s own agriculture department (DG Agriculture) produced a
report in July 2007 that warned of the potential damage to the EU
livestock and poultry industries unless its biotech approval process is
speeded up. Numerous EU stakeholders, such as FEFAC, the European feed
association, have campaigned strongly on this issue, pointing out the
damage that could be caused if the EU is legally barred from importing
crops already approved elsewhere but have not received European
approval.
"We hope the EU will respond quickly and positively to this latest
gesture from the United States," Dodson said.
Currently, Bayer’s LibertyLink® soybean (LLS) and Monsanto's Roundup
RReady2Yield™ (RR2Y) soybean have been fully approved for cultivation in
the U.S., and are going through the EU approval process. These soybean
varieties, along with Pioneer's Optimum® GAT® soybean (also going
through the EU approval system) are targeted for commercialization in
the U.S. in the spring of 2009.
"These three varieties are only the start," Dodson said. "Over the
next 10 years or so there are likely to be more than 20 other varieties
coming forward for commercialization. To avoid disruption of trade and
resulting negative impacts on EU livestock production, the EU and its
Member States need to provide timely and science-based approval of these
soybean events."
The EU process is at least a year behind the U.S. and many other
countries, such as China and Japan. It is an intolerable situation that
must be rectified to allow trade to continue uninterrupted. So far,
despite tremendous efforts by the European feed industry, farmers, the
biotechnology industry and U.S. soybean growers, Europe’s politicians
have yet to wake up and see the huge crisis developing around them.
"Applications for both RR2Y and LLS in other major markets such as
Japan, Taiwan, Korea, Mexico and others either already have been
approved by regulatory authorities or are moving ahead in a timely
manner," Dodson said. "It is the EU process that is out of step with the
rest of the world, and as such, does a disservice not only to the EU
farm industry, but also to consumers who can scarcely be blamed for
being confused when the EU’s own scientists say a product is safe, but
politicians hesitate over whether or not to agree with the scientific
assessment."
With a full pipeline of new soybean events making their way toward
commercialization over the coming years, ASA formed a Biotech Working
Group in 2007 to provide a forum for U.S. soybean organizations to
consult with biotechnology companies on their commercialization,
domestic and international regulatory approvals status, and stewardship
plans. ASA’s goals are to bring these new soy technologies to farmers
just as quickly as possible, while at the same time safeguarding
important export markets. To gain support among industry stakeholders,
ASA has also been conducting advocacy missions to the EU to educate and
motivate key livestock, feed industry, EU and Member State officials
about the soy events now being developed.
"Some EU officials and Member States are finally beginning to speak
out publicly against the EU’s ill-functioning biotech approval system,"
Dodson said. "ASA’s Biotech Working Group is serving an important
function because we are finding stakeholders and officials that are very
unaware of the issue and its possible consequences for the European feed
and livestock industries. They have expressed appreciation for the
briefings and asked for the continued support of U.S. soybean growers."
ASA is the policy advocate and collective voice of its 22,000
producer-members on domestic and international issues of importance to
all U.S. soybean farmers.
--30--
For more information contact:
Johnny Dodson, ASA First Vice President, (731) 286-2268, johnnydodson@bellsouth.net
Bob Callanan, ASA Communications Director, 314/576-1770, bcallanan@soy.org
Access this release at http://www.soygrowers.com/newsroom/news.htm
|